Hims & Hers stock drops 30% after Novo Nordisk ends Wegovy deal

From Yahoo Finance: 2025-06-23 11:39:00

Hims & Hers stock dropped by 30% after Novo Nordisk terminated a collaboration to offer Wegovy on Hims’ platform due to alleged law violations. Compounded GLP-1 drugs were made during shortages but continue despite supply stabilization. Hims faces slower growth and FTC rule changes. Pressure to end pharma ads may impact Hims. Hormone replacement therapy offers potential growth for Hims. 1. The stock market saw record gains today with the S&P 500 reaching an all-time high of 4,500 points. This surge was driven by strong corporate earnings and positive economic data, with tech and healthcare sectors leading the way.

2. Hurricane Ida made landfall in Louisiana as a Category 4 storm, bringing destructive winds and heavy rainfall. Over a million residents were left without power and major flooding was reported in several areas. Emergency response teams are working to assess the damage and provide assistance to those affected.

3. The FDA approved the first COVID-19 vaccine, developed by Pfizer-BioNTech, for full authorization. This decision comes after rigorous testing and analysis showed the vaccine’s safety and effectiveness in preventing severe illness and death. Health officials are urging more Americans to get vaccinated to curb the spread of the virus.

4. Scientists have discovered a new species of dinosaur in Argentina, named Llukalkan aliocranianus. This carnivorous dinosaur had a unique skull structure with sharp teeth and large eye sockets, suggesting advanced hunting abilities. The discovery sheds light on the diverse range of dinosaurs that roamed the Earth millions of years ago.



Read more at Yahoo Finance: Hims & Hers stock plummets after Novo Nordisk ends Wegovy direct sales deal